BioCryst Plummets After Hereditary Angioedema Drug Disappoints In Study
February 08, 2016 at 13:19 PM EST
Shares of BioCryst Pharmaceuticals are plunging in morning trading after the biotechnology company reported disappointing clinical trial results for its potential hereditary angioedema treatment.
